CDT Equity Inc.CDT
Price (close)
$0.08
Market cap
—
P/E
—
Revenue (TTM)
—
Net income
-$37.1M
Dividend yield
—
1-year total return
-100.0%
Net margin
—
Revenue growth
—
Debt / equity
—
What CDT Equity Inc. does.
high-potential therapeutic assets through scientific innovation and strategic partnerships. The Company has evolved into a broader, more
agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development
Company’s strategy is centered on unlocking the untapped value of clinical-stage compounds, particularly those deprioritized by
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | — | -$4.9M | -$535,000 | -$17.8M | -$39.2M |
| Free cash flow | — | — | — | -$9.7M | — |
More on CDT.
- CDT Equity Inc. summary
- CDT Equity Inc. financial statements
- CDT Equity Inc. key metrics
- CDT Equity Inc. health scores and style box
- CDT Equity Inc. earnings
- CDT Equity Inc. dividends
- CDT Equity Inc. valuation
- CDT Equity Inc. ownership and insiders
- CDT Equity Inc. peers
Figures from CDT Equity Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.